z-logo
open-access-imgOpen Access
Mycobacterium tuberculosisHeat Shock Fusion Protein Enhances Class I MHC Cross-Processing and -Presentation by B Lymphocytes
Author(s) -
Aaron A.R. Tobian,
Clifford V. Harding,
David H. Canaday
Publication year - 2005
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.174.9.5209
Subject(s) - mhc class i , antigen processing , cross presentation , biology , heat shock protein , antigen presentation , epitope , hsp70 , t cell , major histocompatibility complex , fusion protein , mhc class ii , cd8 , mycobacterium tuberculosis , microbiology and biotechnology , priming (agriculture) , virology , antigen , immune system , immunology , tuberculosis , biochemistry , gene , medicine , botany , germination , pathology , recombinant dna
Exogenous heat shock protein (HSP):peptide complexes are processed for cross-presentation of HSP-chaperoned peptides on class I MHC (MHC-I) molecules. Fusion proteins containing HSP and Ag sequences facilitate MHC-I cross-presentation of linked antigenic epitopes. Processing of HSP-associated Ag has been attributed to dendritic cells and macrophages. We now provide the first evidence to show processing of HSP-associated Ag for MHC-I cross-presentation by B lymphocytes. Fusion of OVA sequence (rOVA, containing OVA(230-359) sequence) to Mycobacterium tuberculosis HSP70 greatly enhanced rOVA processing and MHC-I cross-presentation of OVA(257-264):K(b) complexes by B cells. Enhanced processing was dependent on linkage of rOVA sequence to HSP70. M. tuberculosis HSP70-OVA fusion protein enhanced cross-processing by a CD91-dependent process that was independent of TLR4 and MyD88. The enhancement occurred through a post-Golgi, proteasome-independent mechanism. These results indicate that HSPs enhance delivery and cross-processing of HSP-linked Ag by B cells, which could provide a novel contribution to the generation of CD8(+) T cell responses. HSP fusion proteins have potential advantages for use in vaccines to enhance priming of CD8(+) T cell responses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom